Journey of an mAb through IND and BLA filing

March 23, 2022

Your monoclonal antibody candidates need extensive stability characterization along their journey to become commercial drugs. This is done to ensure the quality and safety of the final drug for both clinical trials and marketing approval by the FDA. 

This infographic outlines a typical timeline to launch a new mAb-based drug. It focuses on the role of stability studies during the filing of the Investigational New Drug (IND) application – to authorize clinical investigations, and also the Biologics License Application (BLA) – the request for FDA authorization to market a mAb therapeutic.

Learn about the definitions and objectives of both IND and BLA processes, and the importance of stability studies throughout the different phases of approval.

Timeline infographic on IND and BLA processes and role of stability studies during the FDA filing process

Previous
The biologics researcher's guide to DLS
The biologics researcher's guide to DLS

Up next
Prometheus Panta: The new gold standard for biologics characterization
Prometheus Panta: The new gold standard for biologics characterization

Choosing the right stability characterization tool for your biologics research is a big commitment. You’re ...

Looking for the optimal formulation for your biologics candidates?

NanoTemper tools can help

Find out how